Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks. (September 2016)

Record Type:
Journal Article
Title:
Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks. (September 2016)
Main Title:
Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks
Authors:
Farnier, M.
Colhoun, H.M.
Sasiela, W.J.
Edelberg, J.
Asset, G.
Robinson, J.G.
Abstract:
Is Part Of:
Atherosclerosis. Volume 252(2016)
Journal:
Atherosclerosis
Issue:
Volume 252(2016)
Issue Display:
Volume 252, Issue 2016 (2016)
Year:
2016
Volume:
252
Issue:
2016
Issue Sort Value:
2016-0252-2016-0000
Page Start:
e254
Page End:
Publication Date:
2016-09
Subjects:
Arteriosclerosis -- Periodicals
Electronic journals
616.136
Journal URLs:
http://www.sciencedirect.com/science/journal/00219150 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00219150 ↗
http://www.elsevier.com/journals ↗
DOI:
10.1016/j.atherosclerosis.2016.07.070 ↗
Languages:
English
ISSNs:
0021-9150
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - 1765.874000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
4850.xml